Newsletter

Menu

Bio-Path’s stock tanks as company delivers loss for Q1

By Staff Correspondent |
Earnings Update by AlphaStreet

Bio-Path Holdings Inc.’s (NASDAQ: BPTH) shares were down 3.2% in morning hours on Thursday after the company reported its first quarter 2019 earnings results.

The bio-tech company reported a net loss of $1.5 million, or $0.89 per share, for the quarter compared to a loss of $1.9 million, or $3.38 per share, in the prior-year period.

R&D expenses decreased to $0.4 million from $0.9 million in the prior-year period, mainly due to lower clinical trial expenses as the operations between Stage 1 and Stage 2 of the Phase 2 clinical trial in AML were modified to include venetoclax combination treatment with prexigebersen.

In April, Bio-Path presented data from preclinical studies supporting the potential of BP1003, a novel liposome-incorporated STAT3 oligodeoxynucleotide inhibitor, for the treatment of pancreatic cancer, non-small cell lung cancer and acute myelogenous leukemia at the American Association for Cancer Research (AACR) Annual Meeting.

The company anticipates the completion of the Investigational New Drug-enabling studies in 2019 through early 2020, and the filing of an IND application for a Phase 1 study of BP1003 for the treatment of pancreatic cancer in 2020.

In March 2019, Bio-Path issued 712,910 shares of its common stock at a price of $25.95 per share, for gross proceeds of approx. $18.5 million in one transaction. The company also completed two other smaller offerings during the first quarter.

As of March 31, 2019, Bio-Path had cash of $19.3 million, compared to $1 million at December 31, 2018. Bio-Path has not generated significant revenues to date. According to its SEC filings, the company’s ability to generate revenues will depend heavily on the successful development and eventual commercialization of its drug candidates.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Advertisement

More on this Company

227 responses to “Bio-Path’s stock tanks as company delivers loss for Q1”

  33. Maillot de football

    […]Wonderful story, reckoned we could combine a handful of unrelated data, nonetheless definitely really worth taking a search, whoa did a single learn about Mid East has got additional problerms as well […]

  108. FiverrEarn

    […]Wonderful story, reckoned we could combine a few unrelated data, nonetheless definitely worth taking a search, whoa did a single master about Mid East has got far more problerms too […]

  116. Kuliah Termurah

    […]Wonderful story, reckoned we could combine a handful of unrelated information, nonetheless actually really worth taking a search, whoa did a single study about Mid East has got additional problerms also […]

  118. FiverrEarn

    […]we prefer to honor numerous other world wide web web sites around the web, even if they aren’t linked to us, by linking to them. Beneath are some webpages worth checking out[…]

  120. FiverrEarn

    […]we like to honor numerous other world wide web sites around the net, even when they aren’t linked to us, by linking to them. Below are some webpages really worth checking out[…]

  130. nang delivery

    […]Wonderful story, reckoned we could combine several unrelated data, nevertheless definitely really worth taking a look, whoa did one find out about Mid East has got more problerms at the same time […]

  153. masumintl.com

    […]we prefer to honor many other world-wide-web web sites around the internet, even though they aren’t linked to us, by linking to them. Beneath are some webpages really worth checking out[…]

  158. blue french bulldog

    […]Wonderful story, reckoned we could combine a handful of unrelated data, nevertheless seriously really worth taking a appear, whoa did one particular find out about Mid East has got much more problerms too […]

  162. cam sex

    […]we prefer to honor many other online websites on the internet, even though they aren’t linked to us, by linking to them. Beneath are some webpages really worth checking out[…]

Leave a Reply

Top